


Enantioselective Total Synthesis of the Marine Alkaloid Lepadin B

Naoki Toyooka,* Maiko Okumura, and Hiroki Takahata*

Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930-0194, Japan

Received January 26, 1999

The decahydroquinoline alkaloids continue to be of interest as synthetic targets due to their intriguing biological properties,¹ and several methods for the enantioselective construction of this ring system have been reported.² The structurally interesting decahydroquinoline alkaloids lepadins A (**1**), B (**2**), and C (**3**), isolated from the tunicate *Clavelina lepadiformis* by Steffan³ and Andersen and co-workers,⁴ showed significant cytotoxic activity toward a variety of murine and human cancer cell lines.⁴ Although their relative stereochemistry has been determined by the extensive NMR studies, the absolute stereochemistry is still unknown.




We planned a new strategy for the construction of the *cis*-hexahydroquinolinone ring system (**i**) based on an intramo-

lecular aldol type of cyclization of the functionalized piperidine (**ii**) accompanying the epimerization at the C-3 position. It also seemed likely that this hexahydroquinolinone would lead to desired trisubstituted decahydroquinoline core for the synthesis of lepadins with correct stereochemistry at the C-5 position using the conjugate addition.

We have previously shown that the efficient synthesis of the piperidone **4** as a chiral building block for alkaloid synthesis⁵ and its application to the synthesis of the marine alkaloid clavicipines A and B.⁶ Herein, we describe the first enantioselective total synthesis of lepadin B (**2**) starting from **4** using the novel strategy mentioned above as the key step and the determination of its absolute stereochemistry.

Debenzylation of the enantiopure lactam **5**,⁵ obtained from **4** in four steps, under Birch condition followed by protection of the resulting amide with methyl chloroformate gave the carbamate **6**,⁷ which was converted to vinyltriflate **7**⁸ using Comins' reagent (Scheme 1).⁹ Palladium-catalyzed carbonyl-



^a Key: (a) 85% overall yield for **4**; see ref 5; (b) Na, liquid, NH₃-LiHMDS (91%), then *n*-BuLi, ClCO₂Me, THF, -78 °C to rt (77%); (c) LiHMDS, *N*-(chloro-2-pyridyl)triflimide,⁹ THF, -78 to -50 °C (80%); (d) Pd(PPh₃)₄, Et₃N, Ph₃P, MeOH, CO balloon, DMF, rt (74%); (e) vinyl lithium, CuI, Et₂O, -78 to -30 °C (89%) and **8** (7% recovered); (f) LiOH·H₂O, MeOH-H₂O (3:1), 60 °C; ClCO₂Et, Et₃N, THF, 0 °C; CH₂N₂, Et₂O; PhCO₂Ag, Et₃N, Et₂O (71% in four steps); (g) LiOH·H₂O, MeOH-H₂O (3:1), 60 °C; 1,1'-carbonyldiimidazole, Et₃N, *O,N*-dimethylhydroxylamine-hydrochloride, CH₂Cl₂, 0 °C to rt (83% in two steps); (h) MeMgBr, THF, 0 °C to rt (97%); (i) OsO₄, NaIO₄, dioxane-H₂O (1:1), rt (84%).

ation of **7** using Cacchi's procedure¹⁰ afforded the enecarbamate **8**, which was subjected to conjugate addition of in situ generated divinylcuprate to give the 2,3,4,6-tetrasubstituted piperidine **9** as a single isomer.¹¹ Carbon-chain

(1) Daly, J. W.; Garraffo, H. M.; Spande, T. F. In *The Alkaloids*; Cordell, G. A., Ed.; Academic Press: New York, 1993; Vol. 43, pp 185–288. Daly, J. W. In *The Alkaloids*; Cordell, G. A., Ed.; Academic Press: New York, 1998; Vol. 50, pp 141–169.

(2) Several strategies for the chiral synthesis of the *cis*-decahydroquinoline alkaloid pumiliotoxin C have been reported; see: Oppolzer, W.; Flaskamp, E. *Helv. Chim. Acta* **1977**, *60*, 204–207. Royer, M. B. J.; Grierson, D. S.; Husson, H.-P. *Tetrahedron Lett.* **1986**, *27*, 1569–1572. Schultz, A. G.; McCloskey, P. J.; Court, J. J. *J. Am. Chem. Soc.* **1987**, *109*, 6493–6502. Murahashi, S.; Sasao, S.; Saito, E.; Naota, E. *J. Org. Chem.* **1992**, *57*, 2521–2523; *Tetrahedron* **1993**, *49*, 8805–8826. Comins, D. L.; Dehghani, A. *J. Chem. Soc., Chem. Commun.* **1993**, 1838–1839. Naruse, M.; Aoyagi, S.; Kibayashi, C. *Tetrahedron Lett.* **1994**, *35*, 9213–9216; *J. Chem. Soc., Perkin Trans. 1* **1996**, 1113–1124. Toyota, M.; Asoh, T.; Fukumoto, K. *Tetrahedron Lett.* **1996**, *37*, 4401–4404. Davies, S. G.; Bhalay, G. *Tetrahedron: Asymmetry* **1996**, *7*, 1595–1596. Riechers, T.; Krebs, H. C.; Wartchow, R.; Habermehl, G. *Eur. J. Org. Chem.* **1998**, 2641–2646. Two strategies for the construction of *trans*-decahydroquinoline ring system have been reported; see: McCloskey, P. J.; Schultz, A. G. *J. Org. Chem.* **1988**, *53*, 1380–1383. Comins, D. L.; Dehghani, A. *J. Org. Chem.* **1995**, *60*, 794–795.

(3) Steffan, B. *Tetrahedron* **1991**, *47*, 8729–8732.

(4) Kubanek, J.; Williams, D. E.; de Silva, E. D.; Allen, T.; Andersen, R. *J. Tetrahedron Lett.* **1995**, *36*, 6189–6192.

(5) Toyooka, N.; Yoshida, Y.; Momose, T. *Tetrahedron Lett.* **1995**, *36*, 3715–3718.

(6) Toyooka, N.; Yotsui, Y.; Yoshida, Y.; Momose, T. *J. Org. Chem.* **1996**, *61*, 4882–4883.

(7) Satisfactory analytical and spectral data were obtained for all new compounds.


(8) Recently, this type of vinyltriflate has been used as a tool for the synthesis of several types of compound; see: Okita, T.; Isobe, M. *Tetrahedron* **1995**, *51*, 3737–3744. Foti, C. J.; Comins, D. L. *J. Org. Chem.* **1995**, *60*, 2656–2657. Luker, T.; Hiemstra, H.; Speckamp, W. N. *Tetrahedron Lett.* **1996**, *37*, 8257–8260; *J. Org. Chem.* **1997**, *62*, 3592–3596. Ha, J. D.; Lee, D.; Cha, J. K. *J. Org. Chem.* **1997**, *62*, 4550–4551. Ha, J. D.; Kang, C. H.; Belmore, K. A.; Cha, J. K. *J. Org. Chem.* **1998**, *63*, 3810–3811.

(9) Comins, D. L.; Dehghani, A. *Tetrahedron Lett.* **1992**, *33*, 6299–6302.


(10) Cacchi, S.; Morera, E.; Ortari, G. *Tetrahedron Lett.* **1985**, *26*, 1109–1112.

elongation at C-2 position on **9** was performed by an Arndt–Eistert sequence to provide the homologated ester **10**. This ester was transformed into ketone **12** via Weinreb's amide¹² **11**, and subsequent oxidative cleavage of the terminal alkene in **12** yielded the aldehyde **13**.

With the requisite aldehyde in hand, the stage was now set for the key intramolecular aldol cyclization. The stereochemistry of C-3 position in **13** was unfavorable for the synthesis of target alkaloid; however, we expected that the epimerization of the C-3 position would be possible during the aldol cyclization step. It is anticipated that the conformation of **13** is restricted to conformer **13-A** owing to A^(1,3) strain and the appendages on C-2 and C-3 in **13-A** lie in no cyclizable trans diaxial relationship. Consequently, this epimerization will proceed first to give **13'-A**, which will cyclize easily to afford the desired 4a,8a-*cis*-hexahydroquinolinone **14**.



Thus, the treatment of **13** with 4 equiv of DBU in refluxing benzene gave the cyclized product in a ratio of 14:1 (in the ¹H NMR spectrum of the crude product), and fractionation by chromatography on silica gel furnished the major product in 60% isolated yield (Scheme 2). The stereochemistry of the




major product was determined to be that of the desired *cis*-hexahydroquinolinone **14** on the basis of the observation of NOEs between Ha and Hb, Ha and Hc on the NOESY experiment.

This enone **14** was subjected to conjugate addition of the anion generated from phenylthiomethyl phenyl sulfone¹³ with *n*-BuLi at -78 to 0 °C to afford the ketone **15** as a 2:1 mixture of the diastereomers (Scheme 3). Radical reduction of the phenylthio group in **15** gave the sulfone **16** as a sole

(11) The stereochemistry of the newly formed C-2 and C-3 positions in **9** was anticipated to be 2*S*,3*R* according to our previous investigation on the Michael addition reaction of the similar system; see: Momose, T.; Toyooka, N. *J. Org. Chem.* **1994**, *59*, 943–945. Toyooka, N.; Tanaka, K.; Momose, T.; Daly, J. W.; Garraffo, H. M. *Tetrahedron* **1997**, *53*, 9553–9574.

(12) Nahm, S.; Weinreb, S. M. *Tetrahedron Lett.* **1981**, *22*, 3815–3818.

(13) Bordwell, F. G.; Jarvis, B. B. *J. Org. Chem.* **1968**, *33*, 1182–1185.

Scheme 3^a

^a Key: (a) PhS-CH₂-SO₂-Ph, *n*-BuLi, THF, -78 to -10 °C (78%, 14% recovered of **14**); (b) *n*-Bu₃SnH, AIBN, benzene, reflux (85%); (c) NaBH₄, CH₂Cl₂-MeOH (10:1), 0 °C; (d) 1,1'-thiocarbonylimidazole, ClCH₂CH₂Cl, reflux (75% in two steps); (e) *n*-Bu₃SnH, toluene, reflux (84%); (f) *n*-PrSLi, HMPA-THF, rt; (g) (Boc)₂O, benzene, reflux (59% in two steps); (h) *n*-BuLi, THF, -78 to -70 °C then 2-heptenal, -78 to -50 °C; (i) Na-Hg, Na₂HPO₄, MeOH, rt (49% in two steps); (j) concd HCl, MeOH, reflux (85%).

product. Thus, the 1,4-addition at the C-5 position of **14** proceeded in a highly stereoselective manner.¹⁴ Deoxygenation of **16** was performed in a three-step sequence. Reduction of **16** with NaBH₄ afforded the alcohol, which was deoxygenated with *n*-Bu₃SnH via Barton's ester¹⁵ to give the product **17**. Deprotection at the methoxycarbonyl group in **17** with *n*-PrSLi in HMPA,¹⁶ followed by treatment of the resulting amine with (Boc)₂O, furnished the Boc derivative **18**. Construction of the octadienyl moiety was accomplished by means of Julia coupling to give diene **19**. The synthesis of **2** was completed by cleaving both the methoxymethyl and Boc protecting groups with acid. The spectral data for trifluoroacetate salt of synthetic **2** [$[\alpha]_D^{26}$ -92.6 (MeOH)] were identical with those for trifluoroacetate salt of natural lepadin B [$[\alpha]_D$ -96 (MeOH)].

In summary, the first total synthesis of lepadin B (**2**) was accomplished by using the intramolecular aldol cyclization of the tetrasubstituted piperidine **3** as the key step, and the absolute stereochemistry of (–)-**2** was verified to be 2*S*,3*S*-, 4*aS*,5*S*,8*aR* by the present chiral synthesis.

Acknowledgment. We are grateful to Professor Raymond J. Andersen, University of British Columbia, for kindly providing us with ¹H and ¹³C NMR spectra of trifluoroacetate salt of natural lepadin B.

Supporting Information Available: Experimental procedures and spectroscopic data for all new compounds.

JO990141N

(14) Highly stereoselective 1,4-addition of this type of enone has been reported; see: Polniaszek, R. P.; Dillard, L. W. *J. Org. Chem.* **1992**, *57*, 4103–4110. Ibuka, T.; Masaki, N.; Saji, I.; Tanaka, K.; Inubushi, Y. *Chem. Pharm. Bull.* **1975**, *23*, 2779–2790.

(15) Barton, D. H. R.; McCombie, S. W. *J. Chem. Soc., Perkin Trans. 1* **1975**, 1574–1585.

(16) Corey, E. J.; Yuen, P. *Tetrahedron Lett.* **1989**, *30*, 5825–5828.